Review
Copyright ©The Author(s) 2021.
World J Hepatol. Oct 27, 2021; 13(10): 1215-1233
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1215
Table 2 Reported data on survivors versus non-survivors in coronavirus disease 2019
Ref.
N (all) n (non-survivors)
Age (year)
Male
Pre-existing CLD
Type of liver disease
Elevated LFTs on admission (%)
LFTs levels on admission. ALT/AST/ALP/GGT (U/L)/TB (μmoL)
Selected complications or clinical outcomes
Cao et al[51]. China N = 102 (n = 17)53 vs 7247.1% vs 76.5%2.4% vs 5.9%-ALT: NR vs 41.1%ALT: NR vs 40ALI: 24.7% vs 76.5%; ARDS: 5.9% vs 88.2%; Shock: 3.5% vs 41.1%; MV: 2.4% vs 70.6%
Chen et al[52]. China N = 274 (n = 113)51 vs 6855% vs 73%-HBV surface antigen positivityALT: 19% vs 27%; AST: 16% vs 52%ALT: 20 vs 28; AST: 25 vs 45; ALP: 64 vs 76; GGT: 28 vs 42; TB: 8.4 vs 12.6ALI: 2% vs 9%; ARDS: 52% vs 100%; Shock: 0% vs 41%; MV: 82% vs 16%
Chen et al[53]. China N = 55 (n = 19)172 vs 7750% vs 84.2%2.8% vs 5.3%-ALT: 19.4% vs 31.6%; AST: 50% vs 73.7%ALT: 40 vs 44;AST: 55 vs 78MV: 30.6% vs 68.4%
Du et al[54]. China N = 85265.872.9%5.9%-ALT: 16.5%; AST: 32.9%; TB: 35.3%ALT: 72.9; AST: 94.4; TB: 18.4ALI: 35.3%; ARDS: 74.1%; Shock: 81.2%; MV: 93%3
Wu et al[42]. China N = 84 (n = 44)450 vs 68.577.5% vs 65.9%3.5%5--ALT: 35 vs 39; AST: 38.5 vs 37; TB: 11.6 vs 14.5MV: 57.5% vs 97.8%3; Others reported as association
Yang et al[55]. China N = 92269.853.3%3.3%--ALT: 27; AST: 31; TB: 13.6 ALI: 16.5%; ARDS: 80.2%; MODS: 15.4%
Yang et al[39]. China N = 52 (n = 32)51.9 vs 64.670% vs 66%---TB: 13.1 vs 19.5ALI: 30% vs 28%; ARDS: 45% vs 81%; MV: 35% vs 94%
Zhang et al[44]. ChinaN = 82272.565.9%2.4%-ALT: 30.6%; AST: 61.1%; TB: 30.6%ALT: 26; AST: 72; TB: 13.6Hepatic damage: 78%; Liver-associated death: 1.2%; MV: 40.2%
Zhou et al[43]. China N = 191 (n = 54)52 vs 6959% vs 70%--ALT: 24% vs 48%ALT: 27 vs 40 ARDS: 7% vs 93%; Shock: 0% vs 70%; MV: 2% vs 100%3